2 Information about amivantamab

Marketing authorisation indication

2.1 Amivantamab (Rybrevant, Janssen) is indicated for the 'treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for amivantamab.


2.3 The list price for amivantamab is £1,079 per 50 mg vial (excluding VAT; BNF online, accessed October 2022).

2.4 The company has a commercial arrangement, which would have applied if the technology had been recommended.

  • National Institute for Health and Care Excellence (NICE)